Interplay of host genetics and gut microbiota underlying the onset and clinical presentation of inflammatory bowel diseaseFloris Imhann, Rinse K. Weersma, Arnau Vich Vila et al.|Gut|2016Cited by 800
Complex host genetics influence the microbiome in inflammatory bowel diseaseDan Knights, Ramnik J. Xavier, Mark S. Silverberg et al.|Genome Medicine|2014Cited by 431
Ustekinumab for Crohn’s Disease: Results of the ICC Registry, a Nationwide Prospective Observational Cohort StudyVince Biemans, Frank Hoentjen, Andrea E. van der Meulen‐de Jong et al.|Journal of Crohn s and Colitis|2019Cited by 183
Prior Colorectal Neoplasia Is Associated With Increased Risk of Ileoanal Pouch Neoplasia in Patients With Inflammatory Bowel DiseaseLauranne Derikx, Frank Hoentjen, Dirk J. de Jong et al.|Gastroenterology|2013Cited by 134
Ustekinumab is associated with superior effectiveness outcomes compared to vedolizumab in Crohn’s disease patients with prior failure to anti‐TNF treatmentVince Biemans, C. Janneke van der Woude, Gerard Dijkstra et al.|Alimentary Pharmacology & Therapeutics|2020Cited by 129